Investor Presentation - Q4 and FY ended 31.03.2026
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vimta Labs reported Q4 FY26 total income of Rs 1,120 Mn (up 15.2% YoY) with EBITDA of Rs 421 Mn (37.6% margin) and PAT of Rs 211 Mn (18.9% margin). Full year FY26 total income reached Rs 4,163 Mn, up 19.5% YoY, with EBITDA of Rs 1,489 Mn (35.8% margin) and PAT of Rs 775 Mn (18.6% margin). The company is a leading contract research and testing organization (CRTO) with #1 positions in India for pharma analytical and food testing. Debt-to-equity stands at a very low 0.01 with cash reserves of Rs 650.6 Mn against total debt of Rs 33.3 Mn. Promoter holding is 35.85% with 64.15% free-float.
Strong revenue growth of ~20% YoY reflects robust demand across pharma, food, and environment testing segments. However, FY26 EBITDA margin declined to 35.8% from 36.2% in FY25, indicating margin pressure from higher employee and material costs. The company's debt-free status and strong cash position provide flexibility for future capex and growth investments.